A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 [fluorouracil + folinic acid + oxaliplatin] plus cetuximab versus UFOX [tegafur/uracil + folinic acid + oxaliplatin] plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer

Trial Profile

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 [fluorouracil + folinic acid + oxaliplatin] plus cetuximab versus UFOX [tegafur/uracil + folinic acid + oxaliplatin] plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2014

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Folinic acid; Oxaliplatin; Tegafur/uracil
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FUTURE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 04 Jul 2012 Planned number of patients changed from 400 to 420 as reported by European Clinical Trials Database.
    • 30 Jun 2012 Results presented at the 14th World Congress on Gastrointestinal Cancer.
    • 13 Jun 2011 Planned End Date changed from 1 Jul 2009 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top